Alliance Global Partners Upgrades Aptose Biosciences (TSE:APS) to “Strong-Buy”

Alliance Global Partners upgraded shares of Aptose Biosciences (TSE:APS) (NASDAQ:APTO) to a strong-buy rating in a research note issued to investors on Thursday morning,Zacks.com reports.

Aptose Biosciences Stock Down 7.2 %

Shares of APS opened at C$4.36 on Thursday. The company has a market capitalization of C$187.73 million, a PE ratio of -0.87 and a beta of 1.36. Aptose Biosciences has a 12 month low of C$0.16 and a 12 month high of C$5.29. The stock’s 50-day moving average price is C$8.67 and its two-hundred day moving average price is C$12.27. The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.